Welcome to our dedicated page for Ekso Bionics SEC filings (Ticker: EKSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) files a range of reports and disclosure documents with the U.S. Securities and Exchange Commission that provide detailed insight into its exoskeleton and rehabilitation technology business. As a Nevada corporation listed on the Nasdaq Capital Market, the company submits annual and quarterly reports, current reports on Form 8-K, registration statements, and other filings under Commission File Number 001-37854.
Through its SEC filings, Ekso Bionics reports financial results, balance sheet details, and segment information related to its Enterprise Health and Personal Health activities. Earnings-related 8-K filings furnish press releases that discuss revenue, gross margin, operating expenses, and net loss, along with commentary on factors such as product mix between Enterprise Health and Personal Health devices and service margins. Investors can also review disclosures about cash balances, debt arrangements, and stockholders’ equity.
Current reports on Form 8-K document material events, including registered direct offerings of common stock, secured promissory note and security agreements, reverse stock split actions, and equity awards or severance arrangements for certain executives. For example, the company has filed 8-Ks describing a registered direct offering under an effective Form S-3 shelf registration statement, the terms of a secured term loan used for working capital and general corporate purposes, and the implementation and effective date of a reverse stock split intended to support compliance with Nasdaq’s minimum bid price requirements.
Other 8-K filings outline equity incentive awards, phantom performance-based restricted stock units, and change in control and severance agreements for key executives, including conditions for vesting and severance benefits. These documents provide detail on how Ekso Bionics structures compensation and protections around potential change in control events.
On this SEC filings page, users can access Ekso Bionics’ real-time submissions from the EDGAR system, including Forms 10-K and 10-Q for comprehensive financial and risk factor disclosures, as well as Form 4 and related insider transaction reports when available. AI-powered summaries help explain lengthy filings, highlight key terms in financing and equity agreements, and clarify the implications of capital markets transactions, reverse stock splits, and executive compensation arrangements for EKSO shareholders.
Ekso Bionics Holdings, Inc. received a Schedule 13G reporting a significant ownership position in its ordinary shares. Investor Daniel Asher reports beneficial ownership of 321,763 shares, representing 9.48% of the class, with shared power to vote and dispose of these shares and no sole voting or dispositive power.
Related entity DBA Trading, LLC is identified as a reporting person with shared voting and dispositive power over 156,763 shares and a stated 4.62% of the class. The filing states that Asher is the beneficial owner of DBA Trading, LLC and is deemed to control voting and dispositive power over the shares held by that entity. The certification notes that the securities are not held for the purpose of changing or influencing control of Ekso Bionics.
Ekso Bionics Holdings, Inc. Chief Operating Officer Jason C. Jones reported a sale of company stock in a Form 4 filing. On January 6, 2026, he sold 1,320 shares of common stock at $9.25 per share, with the filing explaining that the sale was made to cover tax withholding obligations from the vesting and settlement of restricted stock awards.
After this transaction, Jones beneficially owned 25,621 shares of Ekso Bionics common stock directly and 3,141 shares indirectly through a 401(k) plan. The filing notes that these share amounts have been adjusted to reflect a 1-for-15 reverse stock split that took effect on June 2, 2025.
Ekso Bionics (EKSO) disclosed a Form 4 for CFO Jerome Wong. He sold 11,288 shares of common stock on November 10, 2025 at $4.799 per share to cover tax withholding upon the vesting and settlement of restricted stock awards.
After the transaction, Wong beneficially owns 26,009 shares directly and 2,876 shares indirectly via a 401(k). Share amounts reflect the issuer’s 1‑for‑15 reverse stock split effected on June 2, 2025.
Ekso Bionics (EKSO) reported an insider transaction by its Chief Operating Officer. On 11/10/2025, the executive sold 9,723 shares of common stock in a single transaction at $4.7990 per share. The filing states the sale was made to cover tax withholding obligations arising from the vesting and settlement of previously reported restricted stock awards.
Following the sale, the reporting person beneficially owns 27,211 shares directly and 3,141 shares indirectly through a 401(k). The company effected a 1‑for‑15 reverse stock split on June 2, 2025, and the reported amounts reflect that adjustment.
Ekso Bionics Holdings (EKSO) reported an insider transaction on Form 4. The reporting person, who serves as CEO and director, sold 23,315 shares of common stock on November 10, 2025 at $4.7990 per share. The filing states the sale was to cover tax withholding obligations arising from the vesting and settlement of restricted stock awards.
After the transaction, the reporting person beneficially owned 78,777 shares directly and 373 shares indirectly through a 401(k). The company previously effected a 1-for-15 reverse stock split on June 2, 2025, and the amounts in the filing reflect that adjustment.
Ekso Bionics Holdings (EKSO) disclosed an insider equity grant on Form 4. On 11/05/2025, the reporting person, a Director and CEO, received 80,000 restricted stock units (RSUs) at a price of $0, granted under the Amended and Restated 2014 Equity Incentive Plan. The award was fully vested at grant and settles in shares upon vesting. Following the transaction, the insider beneficially owned 102,092 shares directly and 373 shares via a 401(k). The company effected a 1-for-15 reverse stock split on 06/02/2025, and reported amounts reflect this adjustment.
Ekso Bionics Holdings (EKSO) reported an insider equity grant on Form 4. On November 5, 2025, the Chief Operating Officer received 15,000 restricted stock units (RSUs) at a stated price of $0. The filing states the award was fully vested at grant under the company’s Amended and Restated 2014 Equity Incentive Plan.
Following the transaction, the reporting person beneficially owns 36,934 shares directly and 3,141 shares indirectly via a 401(k). Share amounts reflect the 1-for-15 reverse stock split effected on June 2, 2025.
Ekso Bionics (EKSO) reported an insider equity award for its Chief Financial Officer. On 11/05/2025, the officer acquired 19,500 restricted stock units (RSUs) at $0 under the Amended and Restated 2014 Equity Incentive Plan. The filing states each RSU equals one share and the award was fully vested at grant.
Following the transaction, the officer beneficially owned 37,297 shares directly and 2,876 shares indirectly via a 401(k). The company previously implemented a 1-for-15 reverse stock split on June 2, 2025, and amounts reflect that adjustment.
Ekso Bionics Holdings approved new executive equity awards on November 5, 2025. Scott Davis, Jerome Wong, and Jason Jones received fully vested RSUs covering 80,000, 19,500, and 15,000 shares, respectively. Each also received cash‑settled Phantom PSUs covering 185,000, 40,000, and 32,000 notional shares that vest only if two conditions are met within five years: a Change in Control and a Stock Price of at least $7.50 as defined.
The company also entered into new Change in Control and Severance Agreements with each executive, replacing prior arrangements. If terminated outside a Change in Control, base salary continues for 6 months (or 9 months for Mr. Davis). If terminated within the Change in Control period (or upon Good Reason), severance includes a lump sum of 9 months base salary (or 18 months for Mr. Davis), COBRA premiums for the same periods, and full acceleration of time‑based equity awards. Payments require a release and include a 280G best‑net cutback provision.
Ekso Bionics Holdings, Inc. announced a registered direct offering of 769,490 shares of common stock at $4.81 per share. The company expects approximately $3.2 million in net proceeds after fees and expenses, with intended uses for general corporate purposes, including R&D, SG&A, strategic initiatives, and working capital. The transaction is expected to close on or about October 30, 2025, subject to customary closing conditions.
In connection with the offering, Ekso entered a placement agency agreement with Lake Street Capital Markets. The company will pay a cash fee equal to 6% of gross proceeds and issue a placement agent warrant to purchase up to 15,389 shares at an exercise price of $4.81 per share. The placement agent warrant was offered in reliance on Section 4(a)(2) and the shares issuable upon exercise have not been registered.